Old and new acetylcholinesterase inhibitors for Alzheimer’s disease

Expert Opinion on Investigational Drugs

Volumn 25, Issue 10, 2016, Pages 1181-1187

  Galimberti, Daniela ^a   Scarpini, Elio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetylcholinesterase inhibitors (AChEI); Alzheimer s disease (AD); clinical trial

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ANIMAL; DISEASE COURSE; DRUG DESIGN; HUMAN; METABOLISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ACETYLCHOLINE; AGED; ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84988452879     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1080/13543784.2016.1216972     Document Type: Review

References (55)

1. J.Cummings, B.Winblad A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev Neurother. 2007;7(11):1457–1463.
2. J.Birks. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD005593.• Comparison of efficacy of currently used AChEIs treatments.
3. D.Braida, M.Sala. Eptastigmine:ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001;7(4):369–386.
4. J.Klein. Phenserine. Expert Opin Investig Drugs. 2007;16(7):1087–1097.
5. B.Winblad, E.Giacobini, L.Frölich, et al. Phenserine efficacy in Alzheimer’s disease. J Alzheimers Dis. 2010;22(4):1201–1208.
6. J.Li, H.M.Wu, R.L.Zhou, et al. Huperzine A for Alzheimer’s disease. Cochrane Database Syst Rev. 2008. doi:10.1002/14651858.CD005592.pub2.
7. G.Yang, Y.Wang, T.Jinzhou, et al. Huperzine A for Alzheimer’s disease:a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013;8(9):e74916.
8. Available from:https://clinicaltrials.gov/ct2/show/NCT00377715?term=NCT00377715&rank=1
9. R.S.Doody, S.I.Gavrilova, M.Sano, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease:a randomised, double-blind, placebo-controlled study. Lancet. 2008;372(9634):207–215.
10. Available from:https://clinicaltrials.gov/ct2/show/NCT00912288?term=dimebon&rank=8
11. Available from:https://clinicaltrials.gov/ct2/show/NCT00675623?term=dimebon&rank=4
12. Available from:http://www.alzforum.org/news/research-news/concert-trial-dimebon-falls-flat
13. Available from:https://clinicaltrials.gov/ct2/show/NCT00555204?term=ABT-089&rank=3
14. R.A.Lenz, Y.L.Pritchett, S.M.Berry, et al. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015;29(3):192–199.
15. Available from:https://clinicaltrials.gov/ct2/show/NCT00454870?term=MEM+3454&rank=3
16. Available from:https://clinicaltrials.gov/ct2/show/NCT00884507?term=MEM+3454&rank=4
17. P.J.Nathan, R.Boardley, N.Scott, et al. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer’s disease:a preliminary investigation. Curr Alzheimer Res. 2013;10(3):240–251.
18. Available from:https://clinicaltrials.gov/ct2/show/NCT01009255?term=GSK239512&rank=5
19. R.A.Grove, C.M.Harrington, A.Mahler, et al. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res. 2014;11(1):47–58.
20. Available from:https://www.gsk.com/media/850046/product-pipeline-november-2015.pdf
21. Available from:https://clinicaltrials.gov/ct2/results?term=NCT00744978&Search=Search
22. A.D.Medhurst, A.R.Atkins, I.J.Beresford, et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007;321(3):1032–1045.
23. R.S.Bitner, S.Markosyan, A.L.Nikkel, et al. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease. Neuropharmacology. 2011;60(2–3):460–466.
24. Available from:https://clinicaltrials.gov/ct2/show/NCT01018875?term=ABT-288&rank=1
25. G.M.Haig, Y.Pritchett, A.Meier, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer’s dementia. J Alzheimers Dis. 2014;42(3):959–971.
26. Available from:https://clinicaltrials.gov/ct2/show/NCT00948909?term=NCT00948909&rank=1
27. Available from:http://www.alzforum.org/therapeutics/nelonicline
28. Available from:http://www.alzforum.org/news/conference-coverage/clinical-trials-roundup-four-hits-no-home-runs
29. Available from:https://clinicaltrials.gov/ct2/show/NCT01527916?term=NCT01527916&rank=1
30. Available from:https://clinicaltrials.gov/ct2/show/NCT01549834?term=NCT01549834&rank=1
31. L.M.Gault, A.Meier, H.Florian, et al. A phase 2 trial of the efficacy and safety of the alpha7 agonist Abt-126 as an add-on treatment in mild-to-moderate Alzheimer’s Dementia. Alzheimer’s Dement. 2014;10(4 Suppl):P917–P918.
32. A.Othman, A.Meier, C.W.Ritchie, et al. Efficacy and safety of the alpha7 agonist Abt-126 as a monotherapy treatment in mild-to-moderate Alzheimer’s dementia:results of a phase 2b trial. Alzheimer’s Dement. 2014;10(4 Suppl):P137.
33. Available from:https://clinicaltrials.gov/ct2/show/NCT01676935?term=NCT01676935&rank=1
34. Available from:https://clinicaltrials.gov/ct2/show/NCT01690195?term=NCT01690195&rank=1
35. Available from:https://clinicaltrials.gov/ct2/show/NCT01556763?term=NCT01556763&rank=1
36. Available from:https://clinicaltrials.gov/ct2/show/NCT01073228?term=NCT01073228&rank=1
37. Available from:https://clinicaltrials.gov/ct2/show/NCT02004392?term=NCT02004392&rank=1
38. Available from:http://www.alzforum.org/news/conference-coverage/truly-new-deja-vu-five-hopefuls-lights-go-out-after-phase-2
39. O.Weinreb, T.Amit, O.Bar-Am, et al. Ladostigil:a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer’s disease treatment. Curr Drug Targets. 2012;13(4):483–494.
40. Available from:https://clinicaltrials.gov/ct2/show/NCT01354691?term=ladostigil&rank=2
41. Available from:https://clinicaltrials.gov/ct2/show/NCT01429623?term=ladostigil&rank=1
42. Available from:http://www.avphar.com/avraham-pharmaceuticals-announces-successful-second-interim-results-in-phase-2b-study-of-ladostigil-for-the-treatment-of-mild-cognitive-impairment/
43. Available from:http://neurodyn-inc.com/positive-phase-1a-outcome-for-memogain-means-potential-new-treatment-for-alzheimers-disease/
44. Available from:https://clinicaltrials.gov/ct2/show/NCT02342041?term=SUVN-G3031&rank=1
45. J.Misik, J.Korabecny, E.Nepovimova, et al. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats-Is there a potential for Alzheimer’s disease treatment? Neurosci Lett. 2016;612:261–268.
46. W.Luo, Y.Chen, T.Wang, et al. Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities. Bioorg Med Chem. 2016;24(4):672–680.
47. Y.Dgachi, L.Ismaili, D.Knez, et al. Synthesis and biological assessment of racemic benzochromenopyrimidinimines as antioxidant, cholinesterase, and Aβ1−42 aggregation inhibitors for Alzheimer’s disease therapy. Chem Med Chem. 2016;11:1318–1327. [Epub ahead of print]. doi:10.1002/cmdc.201500539.
48. B.M.Abd Razik, H.Osman, M.O.Ezzat, et al. Efficient synthesis and discovery of Schiff bases as potent cholinesterase inhibitors. Med Chem. 2016;12:1. [Epub ahead of print].
49. Y.Li, X.Qiang, Y.Li, et al. Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett. 2016. pii:S0960-894X(16)30204-9. [Epub ahead of print]. doi:10.1016/j.bmcl.2016.02.079.
50. M.Krátký, K.Vorčáková, et al. Novel cholinesterase inhibitors based on O-aromatic N,N-disubstituted carbamates and thiocarbamates. Molecules. 2016;21(2):191. pii:E191. doi:10.3390/molecules21020191.
51. J.Korabecny, M.Andrs, E.Nepovimova, et al. 7-methoxytacrine-p-anisidine hybrids as novel dual binding site acetylcholinesterase inhibitors for Alzheimer’s disease treatment. Molecules. 2015;20(12):22084–22101.
52. Ł.Kuźma, H.Wysokińska, J.Sikora, et al. Taxodione and extracts from salvia austriaca roots as human cholinesterase inhibitors. Phytother Res. 2016;30(2):234–242.
53. L.F.N.Lemes, G.de Andrade Ramos, A.S.de Oliveira, et al. Cardanol-derived AChE inhibitors:towards the development of dual binding derivatives for Alzheimer’s disease. Eur J Med Chem. 2016;108:687–700.
54. Jack CR Jr, Knopman DS, Chételat G, et al. Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol. 2016;12(2):117–124.•• This review demonstrates that about 25% of patients meeting AD clinical criteria did not have amyloid deposition but neurodegeneration due to other types of dementia.
55. C.H.Lin, P.K.Chen, Y.C.Chang, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease:a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75(9):678–685.